Cobra Biomanufacturing has entered into a manufacturing development agreement with GenVec, Inc. for TNFerade, GenVec’s lead candidate for pancreatic cancer. The agreement includes technology transfer, scale-up, and validation of the manufacturing process for the compound through cGMP consistency lots that will be produced at Cobra’s facility in Oxford, UK.        “GenVec selected Cobra based upon their expertise in viral manufacturing and the experience of key staff members with commercial bi...